Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XW004
- Development stage
- Unknown
- Lead developer
- Sciwind Biosciences
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
XW004 is an oral tablet formulation of ecnoglutide, a novel long-acting, acylated human glucagon-like peptide 1 (GLP-1) analogue. It is designed for the treatment of type 2 diabetes mellitus and obesity. Ecnoglutide acts as a cAMP signaling biased GLP-1 receptor agonist, optimized for improved biological activity and stability. The oral formulation uses an absorption enhancer to prevent degradation in the digestive tract, enabling daily or potentially once-weekly dosing. In phase 1 clinical trials, XW004 demonstrated significant reductions in body weight and favorable safety/tolerability consistent with other GLP-1 agonists[1][3][6][8].
- Other names
- oral ecnoglutideecnoglutide tablet
02
Targets
Beyond the preview
Go deeper on XW004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XW004.